GenoMed awarded second patent for treatment of acute kidney failure

By Elaine Rigoli

Tampa, Fla., March 1 - GenoMed announced Wednesday that it received its second patent - U.S. Patent No. 6,998,404 - for the treatment or prevention of acute renal failure, which is typically caused by dehydration.

Acute kidney failure currently requires a lengthy hospital stay, often involving daily kidney dialysis in the intensive-care unit, and can be fatal.

The company said that avoiding dialysis should greatly improve patient survival and lower health care costs.

"Our patented protocol should be of immediate use to every hospital around the world, especially in places without convenient dialysis. It should be especially useful in disaster zones like New Orleans and earthquakes, as well as the battlefield, where people get dehydrated and go into kidney failure but can't be dialyzed right away," said chief executive officer and chief medical officer David Moskowitz in a company statement.

"In a pilot series, our protocol was safe and effective in a dozen newborns and nine adults, including several patients with combined liver and kidney failure, so-called hepato-renal syndrome."

St. Louis-based GenoMed finds disease-causing genes and uses this knowledge to devise new treatment strategies.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.